Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

Find out where we’ve been featured

Find out where we’ve been featured
Created on 11-12-2019

It’s been a very busy but exciting couple of months for us. You may have seen us in the national or...
MediSieve Continues Growth Trajectory with Latest Award

MediSieve Continues Growth Trajectory with Latest Award
Created on 13-11-2019

Medical device company MediSieve Ltd, has been announced as a winner of the ‘Breakthrough Medical o...